Literature DB >> 7939947

Pharmacokinetics of praziquantel in patients with opisthorchiasis.

K Na Bangchang1, J Karbwang, S Pungpak, B Radomyos, D Bunnag.   

Abstract

The pharmacokinetics of praziquantel was investigated in 9 Thai male patients with asymptomatic opisthorchiasis (stool positive) and 9 patients (6 males, 3 females) with moderately advanced infection (hepatomegaly). The geometric means of the pretreatment Opisthorchis viverrini egg count in these patients were 2,950 vs 4,468 eggs per gram of stool. The results indicate the impairment of metabolism of praziquantel in the moderately advanced stage opisthorchiasis. The pharmacokinetics of the drug in these patients during the acute infection was markedly altered when compared with that after recovery and in patients with early stage of the infection. The clearance rate (Cl/f) was significantly reduced [medians and ranges of 106 (43-242) vs 192 (112-692) and 171 (133-427) ml/min/kg] and the t1/2z and MRT were prolonged [t1/2z: 3.8 (2.0-6.2) vs 2.7 (1.7-4.3) and 2.3 (1.7-2.8) hours; MRT: 6.2 (3.2-11.0) vs 4.6 (2.7-6.2) and 4.5 (2.9-5.1) hours]. In addition, AUCo-alpha was significantly greater [6.0 (2.5-15.6) vs 3.5 (0.6-6.0) and 3.9 (1.6-5.0) micrograms hour/ml].

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7939947

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  6 in total

1.  R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverrini.

Authors:  Christine Falcoz; Serge Guzy; Jana Kovač; Isabel Meister; Jean Coulibaly; Somphou Sayasone; David Wesche; Yu-Wei Lin; Jennifer Keiser
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-01-13       Impact factor: 2.745

2.  Pharmacokinetics of Ascending Doses of Praziquantel in Adults Infected with Opisthorchis felineus in Western Siberia, Russian Federation.

Authors:  Alexandra Probst; Daniela Hofmann; Olga S Fedorova; Sofia V Mazeina; Tatiana S Sokolova; Ekaterina Golovach; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2022-09-12       Impact factor: 5.938

3.  Pharmacokinetic Study of Praziquantel Enantiomers and Its Main Metabolite R-trans-4-OH-PZQ in Plasma, Blood and Dried Blood Spots in Opisthorchis viverrini-Infected Patients.

Authors:  Isabel Meister; Jana Kovac; Urs Duthaler; Peter Odermatt; Jörg Huwyler; Fiona Vanobberghen; Somphou Sayasone; Jennifer Keiser
Journal:  PLoS Negl Trop Dis       Date:  2016-05-06

Review 4.  Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review.

Authors:  Luka Verrest; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

5.  Population Pharmacokinetic Modeling of Tribendimidine Metabolites in Opisthorchis viverrini-Infected Adults.

Authors:  Fiona Vanobberghen; Melissa A Penny; Urs Duthaler; Peter Odermatt; Somphou Sayasone; Jennifer Keiser; Joel Tarning
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients.

Authors:  Urs Duthaler; Somphou Sayasone; Fiona Vanobbergen; Melissa A Penny; Peter Odermatt; Jörg Huwyler; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.